Plus Therapeutics (NASDAQ:PSTV) Trading 1.8% Higher

Plus Therapeutics, Inc. (NASDAQ:PSTV)’s share price traded up 1.8% during trading on Monday . The company traded as high as $1.75 and last traded at $1.66. 199,170 shares changed hands during trading, an increase of 523% from the average session volume of 31,949 shares. The stock had previously closed at $1.63.

Plus Therapeutics Stock Down 1.8 %

The stock has a market cap of $6.85 million, a PE ratio of -0.05 and a beta of 0.59. The stock has a 50-day moving average of $1.85 and a 200 day moving average of $1.79.

Plus Therapeutics (NASDAQ:PSTV) last posted its earnings results on Tuesday, March 5th. The company reported ($0.70) EPS for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.08. Plus Therapeutics had a negative return on equity of 805.57% and a negative net margin of 271.04%. The company had revenue of $1.31 million for the quarter, compared to the consensus estimate of $1.26 million. Research analysts forecast that Plus Therapeutics, Inc. will post -0.99 EPS for the current fiscal year.

Plus Therapeutics Company Profile

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead drug candidate is Rhenium-186Re obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.